<?xml version="1.0" encoding="UTF-8"?>
<p id="P22">Demographic, efficacy, and safety outcomes are reported descriptively. No formal comparisons among the CC-486 dosing regimens were planned. OS was estimated using the Kaplan-Meier method. One-year cumulative RPFS rate was based on a competing risk method, in which death without documented progression or relapse is considered a competing risk for progression or relapse. Statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).</p>
